ShowcasesPricing
  1. US-listed companies
  2. BIOGEN INC.

BIOGEN INC.BIIB

Market cap
$33.5B
P/E ratio
27.5x
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Product--------10,88711,38010,6928,8477,9887,247
Revenue from anti-CD20 therapeutic programs--------1,9802,2901,9781,6591,701-
Revenue from anti-CD20 therapeutic programs-------------1,690
Other--------586708775476485-
Contract manufacturing, royalty and other revenue-------------899
Revenues4,7165,0495,5166,9329,70310,76411,44912,27413,45314,37813,44510,98210,1739,836
Cost of Goods and Services Sold4004675458581,1711,2401,4791,6301,8161,9551,8052,1102,2782,533
Research and development---1,4441,8932,0131,9732,2542,5972,2813,9912,5012,2312,462
Selling, general and administrative1,0321,0561,2771,7122,2322,1131,9481,9362,1062,3752,5052,6742,4042,550
Amortization and impairment of acquired intangible assets--------747490465881366241
Collaboration profit sharing25831831885--101121852422337-7-
Collaboration Profit (Loss) Sharing-------------219
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down---------55-92---
(Gain) loss on fair value remeasurement of contingent consideration---139-30-15-6312648651209-
(Gain) loss on fair value remeasurement of contingent consideration---139-30-15-6312648651209-
Acquired in-process research and development245-------------
Research and Development in Process271------120113-7518--
Restructuring charges75192--93331122--131219
Restructuring charges75192--93331122--131219
Gain on sale of building------------504-
Gain on sale of building------------504-
Other (income) expense, net--------2151183497-1,095108-315
Other (income) expense, net--------2151183497-1,095108-315
Total cost and expense3,4683,3243,7074,4425,7485,8736,2986,9307,5647,3358,8958,1416,5828,539
Total cost and expense3,4683,3243,7074,4425,7485,8736,2986,9307,5647,3358,8958,1416,5828,539
Income before income tax (benefit) expense and equity in loss of investee, net of tax1,2301,7111,8552,4813,9474,7674,9335,1295,9007,1265,0481,7453,5921,297
Income tax (benefit) expense3314454716019901,1621,2372,4591,4261,15899253633135
Equity in (income) loss of investee, net of tax----------5353-
Net income8991,2671,3801,8622,9423,5933,6962,6704,4745,8894,0611,7282,9621,162
Net Income (Loss) Attributable to Noncontrolling Interest-10732--746-713143-60172-850
Net income attributable to Biogen Inc.1,0051,2671,3801,8622,9423,5933,7032,6704,4745,8894,0611,7283,0471,162
Earnings Per Share, Basic3.985.095.87.8612.4215.3816.9611.9421.6331.4724.8610.4420.968.02
Earnings Per Share, Diluted3.945.045.767.8112.3715.3416.9311.9221.5831.4224.810.420.877.97